Nuveen Asset Management LLC Acquires 327,754 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Nuveen Asset Management LLC boosted its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 109.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 625,917 shares of the company's stock after purchasing an additional 327,754 shares during the quarter. Nuveen Asset Management LLC owned about 1.36% of Pacira BioSciences worth $11,792,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PCRX. Sterling Capital Management LLC grew its holdings in Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock valued at $26,000 after buying an additional 1,208 shares during the period. Ancora Advisors LLC acquired a new position in shares of Pacira BioSciences in the 4th quarter valued at approximately $26,000. Caitlin John LLC boosted its stake in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after buying an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after buying an additional 513 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company's stock.

Pacira BioSciences Price Performance

Shares of PCRX traded down $0.14 during mid-day trading on Friday, reaching $25.79. The company had a trading volume of 595,420 shares, compared to its average volume of 975,524. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -12.70 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company's 50 day simple moving average is $25.35 and its 200 day simple moving average is $23.07. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.64.

Analyst Upgrades and Downgrades

PCRX has been the topic of a number of recent research reports. HC Wainwright raised their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Barclays increased their price target on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, Needham & Company LLC reduced their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.